UNSPSC 51183106: Glycodiazine or glymidine

This classification denotes an antimuscarinic agent with the molecular formula C19H28NO3, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier A14FB57V1D, chemically known as 3-hydroxy-1,1-dimethylpyrrolidinium bromide .alpha.-cyclopentylmandelate but generally known as glycopyrrolate, which bears US NIH Compound Identifier 3494. European Medicines Agency schedules Glycopyrronium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB02381MIG.

UNSPSC 51183106 Glycodiazine or glymidine, a Commodity code, covers pharmaceutical ingredients and finished-goods formulations for diabetes management and related metabolic conditions sold into state and local government healthcare and institutional pharmacy networks. The code encompasses both raw active pharmaceutical ingredients and finished pharmaceutical products meeting FDA specifications, cGMP certification, and Drug Supply Chain Security Act (DSCSA) compliance, distributed through contracted pharmaceutical wholesalers to state agencies, local health departments, institutional healthcare facilities, and participating government pharmacy programs. Issuing bodies under this code include state health departments, state procurement offices administering cooperative purchasing vehicles, and multistate purchasing alliances coordinating procurement on behalf of multiple member jurisdictions.

The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued an RFP in January 2026 (S1070000015802) to establish multiple contracts for generic multi-source pharmaceuticals and OTC products with a response deadline of March 26, 2026. MMCAP's solicitation encompasses this commodity within a broader generic pharmaceutical portfolio distributed across participating state and local government facilities in Minnesota and Oregon. Vendors must maintain relationships with at least two of three authorized wholesalers (AmerisourceBergen Drug Corporation/Cencora, Cardinal Health, and Morris & Dickson Co.), comply with cGMP and DSCSA requirements, carry commercial general liability insurance of $5 million per occurrence, and agree to a 3 percent administrative fee on all contract purchases. Award terms run two years for new vendors with optional extensions at MMCAP's discretion, with contract pricing weighted heavily on price competitiveness (75 percent) and fixed-rate commitment (10 percent), and products must be available in the marketplace by May 15, 2026 with at least one year expiration dating and six-month shelf life from manufacture.